(Q26827973)

language of work or name

1 reference

December 2012

1 reference

1 December 2012

4 references

13 March 2019

24 March 2019

17 November 2019

11 August 2020

5 references

13 March 2019

24 March 2019

17 November 2019

11 August 2020

15

1 reference

page(s)

513-23

1 reference

issue

6

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

copyright license

4 references

13 March 2019

24 March 2019

17 November 2019

on focus list of Wikimedia project

11 August 2020

ScienceSource

0 references

cites work

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Expression and localization of estrogen receptor-beta in murine and human bone

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Lasofoxifene in postmenopausal women with osteoporosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

7 April 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

7 April 2017

1 reference

https://api.crossref.org/works/10.3109/13697137.2012.688079

The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1.

22 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Osteonecrosis of the jaw and the role of bisphosphonates: a critical review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Safety considerations with bisphosphonates for the treatment of osteoporosis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

The OPG/RANKL/RANK system in metabolic bone diseases.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Estrogen receptor gene expression in relation to neuropsychiatric disorders

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

The role of selective estrogen receptor modulators (SERMs) in postmenopausal health

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Safety assessment of raloxifene over eight years in a clinical trial setting

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Immunocytochemical localization of estrogen receptors alpha and beta in the human reproductive organs

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Localization of estrogen receptor-alpha in human and rabbit skeletal tissues.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer

31 May 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Tamoxifen use and osteoporotic fracture risk: a population-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

ACOG committee opinion: Tamoxifen and endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Effect of Raloxifene on all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial: 5-year gynecological outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Management of osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3793274

Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats

28 November 2018

1 reference

12 December 2020

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

12 December 2020

A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women

1 reference

12 December 2020

Raloxifene preserves bone strength and bone mass in ovariectomized rats

1 reference

12 December 2020

Transmission of human herpesvirus 8 by blood transfusion

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

7 January 2021

inferred from DOI database lookup

Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2012.688079

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.3109/13697137.2012.688079

1 reference

release_2xixwvacjbcznayqigjtuhegrm

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2xixwvacjbcznayqigjtuhegrm

24 November 2022